Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).

NCT01752569 is registered in ClinicalTrials.gov with Sheffield Teaching Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT01752569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01752569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).
Lead sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Phase
Phase 1/2
Overall status
Terminated
Start date
June 15, 2012
Completion date
December 20, 2017
Enrollment
19 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related kaposi's sarcoma